Page 70 - Diffuse Largeb Cell Lymphoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article LEXINGTON, Mass., March 16, 2021 /PRNewswire/  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2020. 2020 was a transformative year for Curis, as we made significant progress in our mission to develop the next generation of targeted cancer therapies that meaningfully improve and extend the lives of patients. Despite the difficulties and uncertainty brought about by the ongoing coronavirus pandemic, we significantly advanced and expanded each program in our clinical pipeline, headlined by the very encouraging data from our Phase 1 trials of lead asset, CA-4948, presented in December in conjunction with ASH, said James Dentzer, President and Chief Executive Officer of Curis. We look forward to providing additional updates on our IRAK4 program throughout the year, with

United statesRoche erivedgeJames dentzerCancer therapy evaluation programCuris incAmerican society of hematologyDevelopment expensesExchange commissionRoche groupExperimental therapeutics programChief executive officerUwe platzbeckerRecent operationalAmerican societyAnnual meetingDiffuse largeb cell lymphoma